Rakuten Medical Secures $100M in Series F Funding for Alluminox Photoimmunotherapy Development

Rakuten Medical just locked a $100M Series F on Jan 7, 2026, and this was not a quiet raise slipped in between meetings. Oversubscribed. 2x the original target. Total capital now sitting around $866.8M. San Diego address, global posture, and a biotech arc that started back in 2010 as Aspyrian Therapeutics. Miguel Garcia-Guzman did not build this company for fast applause. He built it for science that survives scrutiny, timelines that test patience, and outcomes that actually move needles in oncology.

The inflection point came in 2013, when Hiroshi "Mickey" Mikitani stepped in, not as a brand-name investor chasing allocation, but as an operator driven by proximity to the problem. A personal mission met National Cancer Institute science, licensed from the work of Dr. Hisataka Kobayashi, and the result was Rakuten Medical taking shape with intent. The company rebranded in 2019, but the real transformation was internal. Less noise, more discipline. Less promise, more proof.

This Series F was led by TaiAx Life Science Fund L.P., with heavyweight participation from Daiwa Securities, Mitsui Sumitomo Insurance, Sumitomo Mitsui Banking, ABIES Capital, Nexus CVC, and strategic partner OEP Group. SBI Group, Rakuten Group, Inc., and Hiroshi Mikitani returned because progress compounds when execution keeps pace. Largest institutional syndicate in company history is not a coincidence. It is a response to approvals, data, and a commercial footprint that already exists.

Rakuten Medical is not selling optimism. It is selling precision. The Alluminox platform pairs drug and device, using targeted antibodies and light activation to kill cancer cells while sparing surrounding tissue. ASP-1929 is approved and commercial in Japan as Akalux for unresectable head and neck cancer. Revenue is real. Post-market data is real. That matters when a global Phase 3 trial is enrolling across the U.S., Japan, Taiwan, Ukraine, and Poland, with eyes on a 2028 FDA BLA.

The leadership bench reflects grown-up governance. Miguel Garcia-Guzman as Founder and Chief Scientific Officer. Hiroshi Mikitani as CEO. Minami Maeda as President, translating policy, consulting, and commercial rigor into scale. Andrew Liu sharpening capital strategy. Abhijit Bhatia running ops with surgical efficiency. Carlos Garcia owning the tech stack end to end. Suzane San building people systems that do not crack under growth. This is how complex biotech avoids self-inflicted wounds.

Asia carries roughly 50% of global cancer incidence, and Rakuten Medical already knows how to operate there. Japan is not the destination. It is the launchpad. When light becomes a weapon and precision becomes practice, markets tend to pay attention. This round is not about speed. It is about inevitability.